Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)
Technology appraisal
Reference number: TA662
Published:
The Committee meeting for this appraisal which was scheduled for Wednesday 7 October 2020 has been cancelled. As a result, the expected publication date is to be confirmed.
We will provide more information about this appraisal when available.